Gamco Investors INC. ET AL Sells 470 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Gamco Investors INC. ET AL lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) by 14.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,714 shares of the biotechnology company’s stock after selling 470 shares during the quarter. Gamco Investors INC. ET AL’s holdings in BioMarin Pharmaceutical were worth $240,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Atria Wealth Solutions Inc. grew its stake in BioMarin Pharmaceutical by 5.1% during the 3rd quarter. Atria Wealth Solutions Inc. now owns 9,576 shares of the biotechnology company’s stock valued at $847,000 after purchasing an additional 461 shares during the last quarter. Torray Investment Partners LLC lifted its holdings in shares of BioMarin Pharmaceutical by 29.5% in the 3rd quarter. Torray Investment Partners LLC now owns 14,222 shares of the biotechnology company’s stock valued at $1,258,000 after buying an additional 3,241 shares during the period. Amalgamated Bank lifted its holdings in shares of BioMarin Pharmaceutical by 13.4% in the 3rd quarter. Amalgamated Bank now owns 20,667 shares of the biotechnology company’s stock valued at $1,829,000 after buying an additional 2,439 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter valued at about $5,946,000. Finally, Moody Aldrich Partners LLC acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter valued at about $501,000. Hedge funds and other institutional investors own 92.78% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. BMO Capital Markets decreased their price objective on BioMarin Pharmaceutical from $102.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, November 3rd. Cantor Fitzgerald decreased their price objective on BioMarin Pharmaceutical from $120.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Sanford C. Bernstein raised BioMarin Pharmaceutical from an “underperform” rating to a “market perform” rating and set a $82.00 price target for the company in a report on Monday, October 23rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $101.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, December 21st. Finally, Barclays reduced their price target on BioMarin Pharmaceutical from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Nine research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.16.

View Our Latest Analysis on BMRN

Insider Activity

In related news, Director Jean Jacques Bienaime sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $93.99, for a total value of $939,900.00. Following the completion of the transaction, the director now directly owns 425,112 shares in the company, valued at $39,956,276.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Jean Jacques Bienaime sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $93.99, for a total value of $939,900.00. Following the completion of the transaction, the director now directly owns 425,112 shares in the company, valued at $39,956,276.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP George Eric Davis sold 13,764 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $95.30, for a total value of $1,311,709.20. Following the completion of the transaction, the executive vice president now owns 55,710 shares of the company’s stock, valued at $5,309,163. The disclosure for this sale can be found here. Insiders sold 33,764 shares of company stock worth $3,233,509 over the last ninety days. Corporate insiders own 1.84% of the company’s stock.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $88.46 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.54 and a quick ratio of 1.65. The business has a 50 day simple moving average of $93.92 and a 200-day simple moving average of $89.93. The firm has a market capitalization of $16.66 billion, a PE ratio of 114.88, a price-to-earnings-growth ratio of 1.00 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a 1 year low of $76.02 and a 1 year high of $110.67.

About BioMarin Pharmaceutical

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.